6.34
price down icon4.80%   -0.32
after-market Dopo l'orario di chiusura: 6.40 0.06 +0.95%
loading
Precedente Chiudi:
$6.66
Aprire:
$6.67
Volume 24 ore:
11.32M
Relative Volume:
2.32
Capitalizzazione di mercato:
$1.65B
Reddito:
$6.28B
Utile/perdita netta:
$700.00M
Rapporto P/E:
2.355
EPS:
2.6922
Flusso di cassa netto:
$537.00M
1 W Prestazione:
-29.08%
1M Prestazione:
-38.74%
6M Prestazione:
-51.82%
1 anno Prestazione:
-64.48%
Intervallo 1D:
Value
$6.32
$6.84
Intervallo di 1 settimana:
Value
$6.32
$9.28
Portata 52W:
Value
$6.32
$19.05

Organon Co Stock (OGN) Company Profile

Name
Nome
Organon Co
Name
Telefono
551-430-6000
Name
Indirizzo
30 HUDSON STREET, JERSEY CITY
Name
Dipendente
10,000
Name
Cinguettio
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
OGN's Discussions on Twitter

Confronta OGN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - General icon
OGN
Organon Co
6.34 1.73B 6.28B 700.00M 537.00M 2.6922
Drug Manufacturers - General icon
LLY
Lilly Eli Co
813.53 735.18B 53.26B 13.80B -50.20M 15.08
Drug Manufacturers - General icon
JNJ
Johnson Johnson
186.60 450.37B 92.15B 25.12B 20.46B 10.36
Drug Manufacturers - General icon
ABBV
Abbvie Inc
225.14 401.96B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
121.80 238.94B 53.40B 13.68B 16.89B 6.8864
Drug Manufacturers - General icon
MRK
Merck Co Inc
86.58 217.38B 63.43B 16.42B 14.72B 6.4861

Organon Co Stock (OGN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-10-27 Downgrade Piper Sandler Overweight → Underweight
2025-05-02 Downgrade Evercore ISI Outperform → In-line
2024-09-06 Downgrade JP Morgan Neutral → Underweight
2023-11-03 Downgrade Goldman Buy → Neutral
2023-09-21 Iniziato Barclays Overweight
2023-03-16 Iniziato Raymond James Outperform
2022-10-14 Downgrade BofA Securities Neutral → Underperform
2022-09-06 Aggiornamento Piper Sandler Neutral → Overweight
2022-08-05 Downgrade BofA Securities Buy → Neutral
2022-04-27 Iniziato Goldman Buy
2022-04-06 Ripresa Morgan Stanley Equal-Weight
2021-10-07 Iniziato Piper Sandler Neutral
2021-09-01 Iniziato BofA Securities Buy
2021-07-22 Iniziato Citigroup Buy
2021-06-15 Iniziato JP Morgan Neutral
2021-06-11 Iniziato Morgan Stanley Equal-Weight
2021-06-10 Iniziato Evercore ISI Outperform
Mostra tutto

Organon Co Borsa (OGN) Ultime notizie

pulisher
Oct 29, 2025

MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman - GlobeNewswire Inc.

Oct 29, 2025
pulisher
Oct 29, 2025

Organon: Critical Assessment Of The Audit Committee Investigation Results (NYSE:OGN) - Seeking Alpha

Oct 29, 2025
pulisher
Oct 29, 2025

Organon & Co. (NYSE:OGN) Shares Down 6.2% Following Analyst Downgrade - MarketBeat

Oct 29, 2025
pulisher
Oct 29, 2025

Organon (OGN) Is Down 26.2% After CEO Resignation and Audit Reveals Sales Practice Issues – What's Changed - simplywall.st

Oct 29, 2025
pulisher
Oct 29, 2025

Peregrine Capital Management LLC Increases Stock Position in Organon & Co. $OGN - MarketBeat

Oct 29, 2025
pulisher
Oct 28, 2025

Why Organon (OGN) Stock Is Down Today - TradingView

Oct 28, 2025
pulisher
Oct 28, 2025

Organon’s Stock Tumbles Amidst Leadership Shake-Up - StocksToTrade

Oct 28, 2025
pulisher
Oct 28, 2025

Organon hit hard over ousted CEO scandal - The Pharma Letter

Oct 28, 2025
pulisher
Oct 28, 2025

The Bottom Fishing ClubOrganon: Deep Value In Drugs/Medical Products (NYSE:OGN) - Seeking Alpha

Oct 28, 2025
pulisher
Oct 28, 2025

Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co.OGN - FinancialContent

Oct 28, 2025
pulisher
Oct 28, 2025

Organon Investor Alert: CEO Resigns Amid Audit ProbeSecurities Fraud Investigation on Behalf of Organon InvestorsContact Kehoe Law Firm, P.C.OGN - ACCESS Newswire

Oct 28, 2025
pulisher
Oct 28, 2025

Morgan Stanley Maintains Organon & Co(OGN.US) With Hold Rating, Maintains Target Price $10 - 富途牛牛

Oct 28, 2025
pulisher
Oct 28, 2025

Organon’s Stock Sinks, But Deep Value Beckons For Patient Investors - Finimize

Oct 28, 2025
pulisher
Oct 28, 2025

Organon & Co stock hits 52-week low at 7.26 USD - Investing.com Australia

Oct 28, 2025
pulisher
Oct 28, 2025

Organon makes personnel moves after internal probe finds ‘improper’ sales practices - ROI-NJ

Oct 28, 2025
pulisher
Oct 27, 2025

Organon appoints interim CEO amid sales practice investigation By Investing.com - Investing.com Canada

Oct 27, 2025
pulisher
Oct 27, 2025

Organon & Co.’s Promising Phase 3 Study on Tapinarof Cream for Pediatric Plaque Psoriasis - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Organon & Co. (OGN) Faces Investor Scrutiny Amid Improper - GlobeNewswire

Oct 27, 2025
pulisher
Oct 27, 2025

Kaplan Fox is Investigating Organon & Co. (OGN) Following an Announcement of Findings of an Audit Committee Investigation and CEO Resignation - NewMediaWire

Oct 27, 2025
pulisher
Oct 27, 2025

Organon CEO resigns after probe into 'improper' sales practices - FirstWord Pharma

Oct 27, 2025
pulisher
Oct 27, 2025

Biotech Outshines As Healthcare Stocks See Mixed Moves - Finimize

Oct 27, 2025
pulisher
Oct 27, 2025

This Drugmaker Made ‘Improper’ Sales to Meet Guidance. The Stock Plummets 22%. - Barron's

Oct 27, 2025
pulisher
Oct 27, 2025

Organon CEO resigns amid Nexplanon sales probe (updated) - NJBIZ

Oct 27, 2025
pulisher
Oct 27, 2025

Organon CEO stands down amid contraceptive sales malpractice probe - Yahoo Finance

Oct 27, 2025
pulisher
Oct 27, 2025

Stocks making the biggest moves midday: Qualcomm, Fermi, Dyne Therapeutics, Organon, Snowflake and more - CNBC

Oct 27, 2025
pulisher
Oct 27, 2025

This Drugmaker Made ‘Improper’ Sales to Meet Guidance. The Stock Plummets 25%. - Barron's

Oct 27, 2025
pulisher
Oct 27, 2025

Piper Sandler Downgrades Organon to Underweight From Overweight, $5 Price Target - MarketScreener

Oct 27, 2025
pulisher
Oct 27, 2025

Organon Appoints Interim CEO and Board Chair; Reports Results of Audit Committee Investigation - New Jersey Business Magazine

Oct 27, 2025
pulisher
Oct 27, 2025

Organon cut to Underweight at Piper Sandler on internal control concerns - Seeking Alpha

Oct 27, 2025
pulisher
Oct 27, 2025

Organon Appoints Company Executive Joseph Morrissey as Interim CEO - citybiz

Oct 27, 2025
pulisher
Oct 27, 2025

Organon & Co stock hits 52-week low at 7.26 USD By Investing.com - Investing.com South Africa

Oct 27, 2025
pulisher
Oct 27, 2025

Organon CEO Resigns After Probe Finds Improper Sales Practices - Bloomberg.com

Oct 27, 2025
pulisher
Oct 27, 2025

Organon appoints company executive Joseph Morrissey as interim CEO and board chair Carrie Cox as executive chair; announces results of audit committee investigation - MarketScreener

Oct 27, 2025
pulisher
Oct 27, 2025

Organon Appoints Company Executive Joseph Morrissey As Interim CEO And Board Chair Carrie Cox As Executive Chair Announces Results Of Audit Committee Investigation - TradingView

Oct 27, 2025
pulisher
Oct 27, 2025

Organon CEO Kevin Ali to resign after probe into contraceptive sales - Reuters

Oct 27, 2025
pulisher
Oct 27, 2025

Organon CEO Kevin Ali Resigns Amid Audit Probe Into Wholesaler Sales Practices - Stocktwits

Oct 27, 2025
pulisher
Oct 27, 2025

Organon & Co. Announces CEO Changes - MarketScreener

Oct 27, 2025
pulisher
Oct 27, 2025

Organon stock tumbles after CEO resigns amid sales practice investigation By Investing.com - Investing.com UK

Oct 27, 2025
pulisher
Oct 27, 2025

Organon falls as CEO resigns after probe into contraceptive sales - TradingView

Oct 27, 2025
pulisher
Oct 27, 2025

Organon CEO Kevin Ali to resign after probe into wholesaler sales practices - MarketScreener

Oct 27, 2025
pulisher
Oct 27, 2025

Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation - Stock Titan

Oct 27, 2025
pulisher
Oct 27, 2025

Co. (7XP) stock considered safe havenMarket Growth Review & Fast Exit and Entry Trade Guides - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Co. (7XP) stock in 20252025 Big Picture & Capital Efficiency Focused Ideas - newser.com

Oct 27, 2025
pulisher
Oct 26, 2025

Organon & Co. (NYSE:OGN) Given Sell (D+) Rating at Weiss Ratings - MarketBeat

Oct 26, 2025
pulisher
Oct 26, 2025

Co. (7XP) stock survive global slowdown2025 Sector Review & Safe Entry Point Alerts - newser.com

Oct 26, 2025
pulisher
Oct 24, 2025

Assessing Organon Stock After a 39.5% Drop and Recent Portfolio Moves - Yahoo Finance

Oct 24, 2025
pulisher
Oct 23, 2025

Organon (OGN) Laps the Stock Market: Here's Why - sharewise.com

Oct 23, 2025
pulisher
Oct 23, 2025

Organon (OGN) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Oct 23, 2025
pulisher
Oct 22, 2025

Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It - sharewise.com

Oct 22, 2025
pulisher
Oct 21, 2025

Organon & Co. (OGN) Stock Analysis: Exploring a 40.69% Potential Upside Amidst Healthcare Sector Challenges - DirectorsTalk Interviews

Oct 21, 2025
pulisher
Oct 19, 2025

Co. (7XP) stock good for long term investingJuly 2025 Recap & High Accuracy Buy Signal Tips - newser.com

Oct 19, 2025

Organon Co Azioni (OGN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
drug_manufacturers_general SNY
$50.68
price down icon 0.74%
drug_manufacturers_general PFE
$24.29
price down icon 0.86%
$118.50
price up icon 0.53%
$291.77
price down icon 0.11%
drug_manufacturers_general NVO
$51.37
price down icon 1.31%
drug_manufacturers_general MRK
$86.58
price down icon 0.52%
Capitalizzazione:     |  Volume (24 ore):